Diabetes medications for adults with type 2 diabetes: an update
Bolen S, Tseng E, Hutfless S, Segal JB, Suarez-Cuervo C, Berger Z, Wilson LM, Chu Y, Iyoha E, Maruthur NM
Record ID 32016000649
English
Authors' objectives:
To evaluate the comparative effectiveness and safety of monotherapy and metformin-based combination therapy for type 2 diabetes.
Authors' recommendations:
Evidence from this updated systematic review supports metformin as firstline therapy, given its beneficial effects on HbA1c, weight, and cardiovascular mortality (relative to sulfonylureas) and its relative safety profile. In addition, evidence on comparative outcomes associated with different medication classes can be used to facilitate personalized treatment choices by patients and clinicians, guideline development, and decisionmaking by payers and regulators.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
https://www.effectivehealthcare.ahrq.gov/ehc/products/607/2215/diabetes-update-2016-report.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Diabetes Mellitus, Type 2
- Adult
- Humans
- Hypoglycemic Agents
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.